Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Ruxolitinib bij intermediair-1 risico myelofibrose
dec 2017 | MPN, Stamceltransplantatie